3Maassab H F,DeBorde D C.Characterization of an influenza A host range mutant[J].Virology,1983,130:342-350.
4Snyder M H,London W T,Maassab H F,et al.A 36 nucleotide deletion mutation in the coding region of the NS1 gene of an influenza A virus RNA segment 8 specifies a temperature-dependent host range phenotype[J].Virus Res,1990,15:69-83.
6Bruhl P,Kerschbaum A,Kistner O,et al.Humoral and cell-mediated immunity to Vero cell-derived influenza vaccine[J].Vaccine,2000,19:1149-1158.
7Kida H,Brown L E,Webster R G.Biological activity of monoclonal antibodies to operationally defined antigenic regions on the hemagglutinin molecule of A/Seal/Massachusetts/1/80 (H7N7) influenza virus[J].Virology,1982,122:38-47.
8Fortes P,Beloso A,Ortin J.Influenza virus NS1 protein inhibits pre-mRNA splicing and blocks mRNA nucleocytoplasmic transport[J].EMBO J,1994,13:704-712.
9Bullido R,Gomez-Puertas P,Saiz M J,et al.Influenza A virus NEP (NS2 protein) down regulates RNA synthesis of model template RNAs[J].J Virol,2001,75:4912-4917.
10Qiu Y,Nemeroff M.Krug R M.The influenza virus NS1 protein binds to a specific region in human U6 snRNA and inhibits U6-U2 and U6-U4 snRNA interactions during splicing[J].RNA,1995,1:304-316.
二级参考文献38
1Nicholson KG et al. Lancet,2003,362:1733-1745.
2Banzhoff A et al. Gerontology,2003,49:177-184.
3Lavallee P et al. Stroke,2002,33:513-518.
4Ulmer JB, Deck RR, Dewitt CM, et al. Protective immunity by intramuscular injection of low doses of influenza virus DNA vaccines.Vaccine, 1994,12: 1541-1544.
5Fynan EF, Webster RG, Fuller DH, et al. DNA vaccines: protective immunizations by parenteral, mucosal, and gene-gun inoculations. Proc Natl Acad Sci U S A, 1993, 90: 11478-11482.
6Chen Z, Kadowaki S, Hagiwara Y, et al. Cross-protection against a lethal influenza virus infection by DNA vaccine to neuraminidase.Vaccine, 2000,18: 3214-3222.
7Chen Z, Yoshikawa T, Kadowaki S, et al.-Protection and antibody responses in different strains of mouse immunized with plasmid DNAs encoding influenza virus haemagglutinin , neuraminidase and nucleoprotein. J Gen Virol, 1999,80 ( Pt 10):2559-2564.
8Ulmer JB, Donnelly JJ, Parker SE, et al. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science,1993,259:1745-1749.
9Ulmer JB, TONG-MING FU, Deck RR, et al. Protective CD4 + and CD8 + T cells against influenza induced by vaccination with nucleoprotein DNA. J Virol, 1998,72:5648-5653.
10Okuda K, Ihata A, Watabe S, et al. Protective immunity against influenza A virus induced by immunization with DNA plasmid containing influenza M gene. Vaccine, 2001,19: 3681-3691.
7Montagnon B J, Vincent-Falquet J C. Experience with the Vero cell line[J]. Dev Biol Stand, 1998,93:119-123.
8World Health Organization. Requirements for continuous cell lines used for biological substances[J]. WHO Tech Rep Ser, 1987,745: 99-115.
9World Health Organization. Requirements for rabies vaccine (inactivated) for human use produced in continuous cell lines[J]. WHO Tech Rep Ser, 1987,760:167-189.
10Newman C. Serum-free cell culture-the ethical, scientific and economic choice[J]. Biomed Scient, 2003,941-942.
